French pharmaceutical company, Sanofi, has set an ambitious goal to generate annual sales of more than 10 billion euros ($10.76 billion) by 2030. This growth will come from a combination of recently launched and future pharmaceutical products, which will complement the success of its blockbuster anti-inflammatory drug Dupixent and its vaccines.

Focus on Immunology Treatments

Sanofi plans to prioritize research and development efforts in the field of immunology treatments. The company expects to have 25 data readouts for assets at mid to late stages of development and up to 19 regulatory submissions for its pharmaceutical assets in the next two years.

Late-Stage Pipeline Assets and Recent Launches

Sanofi's sales target is supported by its late-stage pipeline assets that have potential in multiple indications, as well as recently launched drugs. Notable new drugs include Altuviiio for the treatment of hemophilia, Sarclisa for blood cancer, and Tzield for diabetes.

Promising Pipeline Assets

Sanofi identifies three pipeline assets, amlitelimab, frexalimab, and SAR441566, as having the potential to exceed EUR5 billion in annual peak sales each. Additionally, the company sees further potential for peak sales ranging from EUR2 billion to EUR5 billion for nine other innovative medicines and vaccines.

Confidence in Growth Potential

Sanofi's Chief Executive, Paul Hudson, expresses confidence in the company's current product portfolio and the strength of its pipeline. He believes that Sanofi is well-positioned to achieve sustainable growth through 2030 and beyond.

Vaccines as a Key Revenue Source

In addition to pharmaceutical products, Sanofi aims to generate over EUR10 billion in annual sales from vaccines by 2030. This includes the recently launched Beyfortus vaccine for the prevention of respiratory syncytial virus (RSV).

Dupixent Sales Outlook

Sanofi anticipates strong growth in Dupixent sales, with an annual growth rate in the double percentage digits from 2023 to 2030. This growth will be driven by expected new indications, such as chronic obstructive pulmonary disease, as well as increased adoption for its current approved uses. The company has previously stated its expectation for Dupixent sales to reach the EUR10 billion mark in 2023.

Healthcare Stocks: A Diamond in the Rough

Thailand Stock Market Decline

Leave A Reply

Your email address will not be published. Required fields are marked *

Related posts

Renaissance Capital Makes Significant Moves in Q4
News

Renaissance Capital Makes Significant Moves in Q4

Renaissance Capital undergoes significant changes in Q4, selling holdings in Airbnb and Palantir while increasing stakes...

European Carmakers and Suppliers: Fourth-Quarter Earnings and 2024 Guidance
News

European Carmakers and Suppliers: Fourth-Quarter Earnings and 2024 Guidance

Analysts predict modest growth in global car sales for European carmakers, while challenges and key players continue to...

Dell Technologies Revenue Declines in Latest Quarter
News

Dell Technologies Revenue Declines in Latest Quarter

Dell Technologies experienced a decline in revenue and net income for the latest quarter. Adjusted earnings per share su...

CD Terms: How to Choose the Right Duration
News

CD Terms: How to Choose the Right Duration

This article explores how to choose the ideal CD term based on duration, interest rates, and market conditions, along wi...